Actively Recruiting
Phase 1b Study of MRX-2843 with Osimertinib to Treat Advanced EGFR Mutant Non-Small Cell Lung Cancer
Led by Emory University · Updated on 2026-03-31
69
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the best dose and side effects of MRX-2843 when combined with osimertinib in patients with advanced non-small cell lung cancer that has an EGFR gene mutation and spread to other parts of the body. This phase Ib trial aims to assess safety, tolerability, and identify the recommended dose for future studies, along with observing tumor response and exploring biomarkers to improve treatment effectiveness. Participants receive osimertinib and MRX-2843 orally once daily for 28-day cycles. Treatment continues as long as the disease does not progress or unacceptable side effects occur. After completing treatment, patients are followed for at least 30 days or until treatment-related side effects improve to mild levels. During the trial, participants undergo regular assessments including tumor measurements and biomarker testing. Researchers monitor safety, side effects, and treatment response over up to 3.5 years. They measure the maximum tolerated dose and progression-free survival at one year. Participants must be able to swallow oral medication and meet specific blood and organ function requirements to take part.
CONDITIONS
Brief Title
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Research Team
C
Conor Steuer, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
